Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 2,332 $ 2,158 $ 6,894 $ 5,108
General and administrative 1,084 1,161 3,506 3,323
Operating loss (3,416) (3,319) (10,400) (8,431)
Other (income) expense:        
Governmental assistance - research incentives 0 (25) 0 (205)
Other (income) expense, net 27 (103) (75) (154)
Total other (income) expense 27 (128) (75) (359)
Loss before income tax expense (3,443) (3,191) (10,325) (8,072)
Income tax expense 7 2 21 20
Net loss (3,450) (3,193) (10,346) (8,092)
Other comprehensive income (loss)        
Unrealized gain (loss) on marketable securities (2) (19) (3) 8
Net loss and comprehensive loss $ (3,452) $ (3,212) $ (10,349) $ (8,084)
Basic and diluted net loss per share (in dollars per share) $ (0.18) $ (0.19) $ (0.55) $ (0.55)
Weighted average shares outstanding – basic and diluted (in shares) 19,035,713 16,689,074 18,863,829 14,652,749